Business
Axcelis designs, manufactures, and services ion implantation and other processing equipment used in semiconductor chip production, with the Purion product family as its main platform.
Axcelis stayed profitable through a semiconductor-equipment downturn, but revenue and earnings fell hard.
The read at a glance✓ Audited against SEC data
- Growth — Revenue -17.6% to $839MWatch
- Profitability — Net income -40.2% to $120MWatch
- Cash quality — FCF -16.8% to $107MWatch
- Margins — Operating margin -649 bps; FCF margin +11 bpsWatch
- Capital — $121M buybacks; no dividend shownWatch
- Balance sheet — Equity +2.2%; no long-term debt shownOK
- Insiders — 0 buys / 7 sellsWatch
- Accounting — Z safe; M-score clean; EQ 82.62OK
Where the revenue comes from
Fiscal 2025, as AXCELIS TECHNOLOGIES INC reports it. History and quarterly detail are in the app.
- Ion Implantation Systems Services And Royalties$824.1M
- Product$792.0M
- New Systems Revenue$571.0M
- After Market$268.0M
- Services$47.0M
Leadership changes
From AXCELIS TECHNOLOGIES INC's own filings, the day they're filed.
- James Coogan · Chief Financial Officer · departureeff. 2026-04-24
- David Ryzhik · Chief Financial Officer · appointmenteff. 2026-03-12
- James Coogan · President · appointmenteff. 2023-09-05
Latest filings
- 8-K · Company announcement2026-08-06
- 10-Q · Quarterly report2026-08-06
- 10-Q · Quarterly report2026-05-08
- 8-K · Company announcement2026-05-07
- 8-K · Company announcement2026-05-06
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about AXCELIS TECHNOLOGIES INC, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.